As we all know the CBD market is gaining popularity over the past couple of years. Yet even more fascinating is the projected estimate Cowen analysts made about the revenue of this market–$16 billion by 2025.
So after screening various small stocks in the CBD sector, I have found one interesting company – Stillcanna Inc (OTCMKTS:SCNNF). The reason to bring this company in front of you is because of the recently announced BIG news – it has signed a definitive agreement to supply Bioscience Enterprises of California with up to C$36 Million worth of CBD Isolate.
On the chart, #SCNNF is trading sideways on the Canadian Exchange. However, the volume has been increasing – signaling increase buying interest. The stock has just started trading on the OTC market this month and we will not be surprised if #SCNNF starts picking up in coming session.
#SCNNF closed at $0.885 on the OTC market on Thursday. Keep an eye on the stock as recent news activities could spark a big rally in the stock in coming sessions.
You should not miss #SCNNF – it might jump to $1.35-1.50 very soon.
About StillCanna
StillCanna Inc. (CSE: STIL) (OTCMKTS:SCNNF) is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe. The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.
Recent News
StillCanna Signs Definitive Agreement With BioSciences Enterprises to Supply C$36 Million Worth of CBD Isolate and Implements a Two-Stage Extraction Plan for Poland
StillCanna Inc. (CSE:STIL) (OTC:SCNNF) (“StillCanna” or the “Company”) is pleased to announce that further to its press release dated March 28, 2019, it has signed a definitive agreement to supply Bioscience Enterprises of California with up to C$36,000,000 worth of CBD Isolate.
To accelerate its product delivery, the Company is implementing a two-stage extraction plan for Poland. Stage one will consist of equipment engineered to optimize the production of CBD Isolate. With permitting in place and equipment ordered for Poland, it is anticipated that the initial line will produce and ship CBD Isolate Q4 of 2019 allowing the Company to begin fulfilling its obligations under the Biosciences agreement.
StillCanna Strengthens Board with Business and Finance Veteran Warren Robinson
VANCOUVER, May 30, 2019 /PRNewswire/ – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce the appointment of Warren Robinson to its Board of Directors. In conjunction with the appointment of Mr. Robinson as director, the Company’s CFO Joel Leonard has resigned from the Board of Directors. Mr. Leonard will continue to operate as the Company’s CFO.
Mr. Robinson will assist StillCanna in its capital markets activities as well as in identifying global expansion initiatives. Mr. Robinson will use his wealth of knowledge and experience to help with increasing the Company’s reach amongst institutional investors and provide the Company with a greater depth of expertise in corporate finance, capital raising/structuring, and mergers & acquisitions activity.